Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option

Elevar Therapeutics announced FDA approval of Lyrfigtu (lirafugratinib) for treating cholangiocarcinoma patients with FGFR2 fusion or rearrangement. The drug demonstrated a 46% objective response rate and 11.8-month median duration of response in the Phase 1/2 ReFocus trial. Lyrfigtu is expected to be available in the U.S. by Q4 2026 and represents a second-line treatment option for this rare bile duct cancer.